Skip to content
Politically.com Search all
Menu

Final rule 2026-11740

Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System

The Food and Drug Administration (FDA) is classifying the Spinal Muscular Atrophy newborn screening test system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the Spinal Muscular Atrophy newborn screening test system. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

Source: FederalRegister.gov API v1Recently refreshed. Last successful refresh: 2026-07-31 22:49:02 UTC.

Source-supplied record

Document details

Document number
2026-11740
Published
Jun 11, 2026
Effective
Jun 11, 2026
Comments close
Not supplied
Federal Register citation
91 FR 35384

Docket identifiers

  • Docket No. FDA-2026-N-5828

CFR references

  • Title 21, part 866